These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. [Results of treatment of patients with advanced multiple myeloma with the vincristine-adriamycin-dexamethasone protocol]. Marisavljević D; Bosković D; Radosević N; Elezović I; Tomin D; Gotić M; Antunović P Srp Arh Celok Lek; 1996; 124(11-12):292-6. PubMed ID: 9132962 [TBL] [Abstract][Full Text] [Related]
3. Melphalan-prednisone versus alternating combination VAD/MP or VND/MP as primary therapy for multiple myeloma: final analysis of a randomized clinical study. Cavo M; Benni M; Ronconi S; Fiacchini M; Gozzetti A; Zamagni E; Cellini C; Tosi P; Baccarani M; Tura S; Haematologica; 2002 Sep; 87(9):934-42. PubMed ID: 12217805 [TBL] [Abstract][Full Text] [Related]
10. [Efficacy Comparison of Low dose Thalidomide Combined with Modified VCMP and VAD regimens for Treatment of Aged MM Patients]. Wang W; Liu HB Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2016 Jun; 24(3):765-8. PubMed ID: 27342506 [TBL] [Abstract][Full Text] [Related]
11. Melphalan-prednisolone and vincristine-doxorubicin-dexamethasone chemotherapy followed by prednisolone/interferon maintenance therapy for multiple myeloma: Japan Clinical Oncology Group Study, JCOG0112. Chou T; Tobinai K; Uike N; Asakawa T; Saito I; Fukuda H; Mizoroki F; Ando K; Iida S; Ueda R; Tsukasaki K; Hotta T; Jpn J Clin Oncol; 2011 Apr; 41(4):586-9. PubMed ID: 21247967 [TBL] [Abstract][Full Text] [Related]
12. VAD-based regimens as primary treatment for multiple myeloma. Alexanian R; Barlogie B; Tucker S Am J Hematol; 1990 Feb; 33(2):86-9. PubMed ID: 2301376 [TBL] [Abstract][Full Text] [Related]
13. Modified adriamycin-vincristine-dexamethasone (m-VAD) in primary refractory and relapsed plasma cell myeloma: an NCI (Canada) pilot study. The National Cancer Institute of Canada Clinical Trials Group. Browman GP; Belch A; Skillings J; Wilson K; Bergsagel D; Johnston D; Pater JL Br J Haematol; 1992 Nov; 82(3):555-9. PubMed ID: 1486035 [TBL] [Abstract][Full Text] [Related]
14. High-dose glucocorticoid treatment of resistant myeloma. Alexanian R; Barlogie B; Dixon D Ann Intern Med; 1986 Jul; 105(1):8-11. PubMed ID: 3717812 [TBL] [Abstract][Full Text] [Related]
15. A randomized study (WOS MM1) comparing the oral regime Z-Dex (idarubicin and dexamethasone) with vincristine, adriamycin and dexamethasone as induction therapy for newly diagnosed patients with multiple myeloma. Cook G; Clark RE; Morris TC; Robertson M; Lucie NP; Anderson S; Paul J; Franklin IM Br J Haematol; 2004 Sep; 126(6):792-8. PubMed ID: 15352982 [TBL] [Abstract][Full Text] [Related]
16. Prospective randomized comparison of vincristine, doxorubicin and dexamethasone (VAD) administered as intravenous bolus injection and VAD with liposomal doxorubicin as first-line treatment in multiple myeloma. Dimopoulos MA; Pouli A; Zervas K; Grigoraki V; Symeonidis A; Repoussis P; Mitsouli C; Papanastasiou C; Margaritis D; Tokmaktsis A; Katodritou I; Kokkini G; Terpos E; Vyniou N; Tzilianos M; Chatzivassili A; Kyrtsonis MC; Panayiotidis P; Maniatis A; Ann Oncol; 2003 Jul; 14(7):1039-44. PubMed ID: 12853344 [TBL] [Abstract][Full Text] [Related]
17. Etoposide and ifosfamide for MP (melphalan and prednisolone)- and VAD (vincristine, adriamycin and dexamethasone)-resistant plasma cell myeloma: a case report. Ikeda K; Abe N; Morioka A; Inoo M; Nagai M; Kubota Y; Irino S Jpn J Med; 1990; 29(5):516-8. PubMed ID: 2089176 [TBL] [Abstract][Full Text] [Related]